852 Winter Street
Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes’ website at www.alkermes.com .
Richard F. Pops- Chairman and Chief Executive Officer
Shane Cooke- President
Kathryn L. Biberstein- Executive Vice President, Chief Compliance Officer and Chief Administrative Officer, and Secretary Alkermes plc
Iain Brown- Senior Vice President, Finance and Chief Accounting Officer
Madeline D. Coffin- Senior Vice President, Human Resources
Elliot W. Ehrich, M.D.- Executive Vice President, Research and Development
James M. Frates- Senior Vice President, Chief Financial Officer
David J Gaffin- Senior Vice President, Chief Legal Officer
Georgianna Harris, Ph.D.- Senior Vice President, Regulatory Affairs
Craig Hopkinson, M.D.- Chief Medical Officer, and Senior Vice President of Clinical Development and Medical Affairs
Blair C. Jackson- Senior Vice President, Business Development
Michael J. Landine- Senior Vice President, Corporate Development
Mark Namchuk, Ph.D.- Senior Vice President, Research, Pharmaceutical and Nonclinical Development
Peter Norman- Vice President, Government Affairs and Policy
Declan O’Connor- Senior Vice President, Operations
Phil Shanahan, Ph.D.- Vice President, Quality Operations
Mark P. Stejbach- Senior Vice President, Chief Commercial Officer
Alkermes Corporate Headquarters
1 Burlington Road
Dublin 4, Ireland
+353 1 772 8000
852 Winter Street
Waltham, MA 02451
+1 781 609 6000
Co Westmeath, Ireland
+353 90 649 5000
1300 Gould Drive
Gainesville, GA 30504
+1 770 531 8100
265 Olinger Circle
Wilmington, OH 45177
+1 937 382 5642
581 articles with Alkermes
Shares of Alkermes were up more than 12% in pre-market trading after the Ireland-based company announced late Friday that its schizophrenia drug was overwhelmingly supported by an advisory committee for the U.S. Food and Drug Administration.
FDA Advisory Committee Votes in Support of ALKS 3831 for the Treatment of Schizophrenia and Bipolar I Disorder
Alkermes plc (Nasdaq: ALKS) today announced positive voting outcomes from the joint meeting of the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, appointed by the U.S. Food and Drug Administration (FDA). The committees met to discuss ALKS 3831 (olanzapine/samidorphan), an inves
The assessment does point to a path for approval, however FDA staff do raise some concerns about the fact that the drug’s makeup includes an opioid antagonist.
Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has posted on its website briefing documents for the Oct. 9, 2020 joint meeting of the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee to review the company's New Drug Application (NDA) f
Alkermes Presents New Clinical Data on ALKS 4230 in Mini Oral Presentation at 2020 European Society for Medical Oncology (ESMO) Virtual Congress
Data Provide Evidence of Clinical Benefit and Tolerability of ALKS 4230 as Monotherapy in Melanoma and in Combination With Pembrolizumab in Multiple Tumor Types
-- New Outcomes Research Analyzed Patterns of Weight Gain and Treatment Interruptions Associated With the Use of Second-Generation Oral Antipsychotics in Patients With Schizophrenia or Bipolar I Disorder -- -- Five Additional Poster Presentations Highlight Data Related to ALKS 3831 and ARISTADA® --
Alkermes plc (Nasdaq: ALKS) announced today that that its Chief Executive Officer, Richard Pops, will participate in a fireside chat at the Cantor Virtual Global Healthcare Conference on Wednesday, Sept. 16, 2020 at 10:40 a.m. ET (3:40 p.m. BST)
Alkermes to Present New Data on Investigational Immuno-Oncology Candidate, ALKS 4230, at the 2020 European Society for Medical Oncology (ESMO) Virtual Congress
Alkermes plc announced that it will present new clinical data related to ALKS 4230, its investigational engineered interleukin-2 variant immunotherapy, at the European Society for Medical Oncology Virtual Congress, taking place Sept. 18-21, 2020.
Virtual FDA Advisory Committee Meeting to Review New Drug Application for ALKS 3831 for Treatment of Schizophrenia and Bipolar I Disorder Tentatively Scheduled for Oct. 9, 2020
Alkermes plc announced that a joint meeting of the U.S. Food and Drug Administration's Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee to review the New Drug Application for ALKS 3831 has been tentatively scheduled for Oct. 9, 2020.
Alkermes Initiates Phase 2 Study Designed to Evaluate Clinical and Immunologic Activity of ALKS 4230 on Tumor Microenvironment in Patients with Advanced Solid Tumors
Alkermes plc announced the initiation of ARTISTRY-3, a new phase 2 study to evaluate the clinical and immunologic effects of ALKS 4230 monotherapy on the tumor microenvironment of a variety of advanced, malignant solid tumors.
American Journal of Psychiatry Publishes Data From Alkermes' Phase 3 ENLIGHTEN-2 Weight Study of ALKS 3831 in Patients With Schizophrenia
Alkermes plc announced the publication of results from the phase 3 ENLIGHTEN-2 clinical trial of ALKS 3831 in the peer-reviewed publication, American Journal of Psychiatry.
Company Reports Second Quarter Revenues of $247.5 Million, GAAP Net Loss per Share of $0.19 and Diluted Non-GAAP Earnings per Share of $0.06
Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, July 29, 2020 to discuss the company's second quarter 2020 financial results. Management will also provide an update on the company.
Alkermes plc announced that it will begin accepting applications for its annual Alkermes Pathways Research Awards® program on July 1, 2020.
Alkermes Awards COVID-19 Relief Fund Grants to 10 Innovative Programs Designed to Address Challenges for Patient Communities
Special Edition of Alkermes Inspiration Grants® Program Focused on Addressing Pandemic-Related Needs of People Living with Addiction, Serious Mental Illness, or Cancer
New Preclinical Data on ALKS 4230 in Combination With Lucitanib to be Presented at 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II
Alkermes plc (Nasdaq: ALKS) and Clovis Oncology, Inc . (Nasdaq: CLVS) today announced positive preclinical data from a study designed to evaluate the combination potential of
Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the 41st Annual Goldman Sachs Global Healthcare Conference on Thursday, June 11, 2020 at 9:40 a.m. ET (2:40 p.m. BST).
Alkermes Highlights New Data From Schizophrenia Portfolio at the American Society of Clinical Psychopharmacology 2020 Annual Meeting
Findings From Qualitative Patient Substudy Evaluating Health-Related Quality of Life in Patients With Schizophrenia and Treatment Satisfaction, Including Treatment with ALKS 3831, to be Presented
Journal of Clinical Psychiatry Publishes Data from Alkermes' ALPINE Study in Patients With Schizophrenia
Phase 3b Study Evaluated Efficacy and Safety of ARISTADA® 2-month Dose, Together With ARISTADA INITIO® One-day Initiation Regimen, in Patients Hospitalized for Acute Schizophrenia
Alkermes Presents New Data From Schizophrenia Portfolio at Virtual 2020 Congress of the Schizophrenia International Research Society
-- E-Poster Presentations Include Results From Completed 52-Week, Open-Label Safety Study of ALKS 3831 in Patients With Schizophrenia -- [14-May-2020] DUBLIN , May 14, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of new data from its schizophrenia portfolio as part of the virtual 2020 Congress of the Schizophrenia International R